MESO Mesoblast Ltd

$14.77

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

As Mesoblast (MESO) approaches its earnings announcement on August 27, the market's focus is on its ability to maintain financial stability amidst a challenging biotech landscape. With an EPS estimate of $0.00 and a revenue projection of $13.20 million, the company is expected to meet the whisper number, reflecting cautious optimism among investors. Despite a lack of recent news, Mesoblast's substantial market cap of over $2 billion underscores its potential in the regenerative medicine sector. Investors will be keenly watching for any strategic updates or developments that could signal future growth, particularly as the company navigates the complexities of clinical trials and regulatory approvals. The upcoming earnings report will be pivotal in assessing Mesoblast's trajectory and its capacity to leverage its innovative pipeline into tangible financial results.

Updated On 11/17/2025

About Mesoblast Ltd

Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.

Website: https://www.mesoblast.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
June
CIK
1345099
Address
LEVEL 38, 55 COLLINS STREET, MELBOURNE, VICTORIA, AU
Valuation
Market Cap
$1.36B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
2.95
Performance
EPS
$-0.94
Dividend Yield
—
Profit Margin
0.00%
ROE
-21.30%
Technicals
50D MA
$14.13
200D MA
$11.33
52W High
$22.00
52W Low
$5.26
Fundamentals
Shares Outstanding
127M
Target Price
$27.00
Beta
2.03

MESO EPS Estimates vs Actual

● Estimated
● Actual

MESO News & Sentiment

Nov 17, 2025 • Benzinga NEUTRAL
James M. O'Brien Appointed Chief Financial Officer at Mesoblast - Mesoblast ( NASDAQ:MESO )
NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( NASDAQ:MESO, ASX:MSB ) ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed ...
Nov 17, 2025 • GlobeNewswire NEUTRAL
James M. O'Brien Appointed Chief Financial Officer at Mesoblast
NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed ...
Nov 10, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Bears are Losing Control Over Mesoblast Limited ( MESO ) , Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Nov 04, 2025 • Benzinga NEUTRAL
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation - Mesoblast ( NASDAQ:MESO )
NEW YORK, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( NASDAQ:MESO, ASX:MSB ) ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S.
Nov 04, 2025 • GlobeNewswire NEUTRAL
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
NEW YORK, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug Administration ( FDA ) has scheduled a meeting in early December to discuss Mesoblast's ...
Oct 29, 2025 • Zacks Commentary SOMEWHAT-BULLISH
All You Need to Know About Mesoblast Limited ( MESO ) Rating Upgrade to Buy
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sentiment Snapshot

Average Sentiment Score:

0.090
50 articles with scored sentiment

Overall Sentiment:

Neutral

MESO Reported Earnings

Aug 27, 2025
Jun 30, 2025 (Pre market)
0.36 Surprise
  • Reported EPS: $-0.04
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: 90.0%
Apr 29, 2025
Mar 31, 2025 (Pre market)
0.14 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.14
  • Whisper: —
  • Surprise %: 100.0%
Feb 26, 2025
Dec 31, 2024 (Pre market)
0.37 Surprise
  • Reported EPS: $-0.04
  • Estimate: $-0.41
  • Whisper: —
  • Surprise %: 90.2%
Oct 30, 2024
Sep 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: 9.7%
Jul 04, 2024
Jun 30, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.36
  • Whisper: —
  • Surprise %: 0.0%
Jun 27, 2024
Mar 31, 2024 (Post market)
0.11 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.11
  • Whisper: —
  • Surprise %: 100.0%
Mar 25, 2024
Dec 31, 2023 (Post market)
0.4 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: 100.0%
Dec 26, 2023
Sep 30, 2023 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-0.12
  • Whisper: —
  • Surprise %: -6.8%
Aug 30, 2023
Jun 30, 2023 (Post market)
0.01 Surprise
  • Reported EPS: $-0.14
  • Estimate: $-0.15
  • Whisper: —
  • Surprise %: 6.7%

Financials